Paediatric Use Marketing Authorisation

The Paediatric Use Marketing Authorisation (PUMA) is a European regulatory pathway designed to promote the development of medicines specifically for children. It provides regulatory incentives, including 10 years of market exclusivity.

PUMA applies to products already authorised in adults but requiring tailored clinical data for paediatric populations.